What are the findings of the PREVAIL and PROTECT AF trials?
The PREVAIL and PROTECT AF trials were prospective randomized evaluations of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy. The trials found that percutaneous closure of the left atrial appendage was non-inferior to warfarin therapy for prevention of stroke in patients with atrial fibrillation, with 5-year outcomes showing a similar rate of stroke in both groups. Additionally, the PREVAIL trial found that the device was associated with a lower rate of major bleeding compared to warfarin therapy. 